Literature DB >> 1812242

Hemangioblastomas: clinical characteristics, surgical results and immunohistochemical studies.

S Lodrini1, G Lasio, C Cimino, F Pluchino.   

Abstract

A surgical series of 59 patients with cerebellar or spinal cord hemangioblastomas or von Hippel-Lindau's (VHL) syndrome is analyzed. The presence of the tumor is easily detected by Computerized Tomography (CT) and Nuclear Magnetic Resonance (NMR), but angiography is still necessary for a correct surgical planning. The value of a sharp distinction among patients with single hemangioblastomas and the ones with Lindau's disease and VHL syndrome is stressed. In fact patients with single cerebellar or spinal hemangioblastomas have a good prognosis, while patients with disseminated hemangioblastomas have a rather poor outlook. Neuropathological studies with immunohistochemical techniques have been performed to identify the nature of the stromal cells of the hemangioblastomas: their origin from glial, endothelial and monociticphagocitic elements seems excluded.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812242

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  4 in total

1.  A Case of Von Hippel Lindau Disease.

Authors:  S Bhargava; A Rao; A Mishra
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Posterior fossa haemangioblastomas.

Authors:  J Julow; K Bálint; P Gortvai; E Pásztor
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

3.  Treatment of recurrent cerebellar hemangioblastoma with external radiotherapy in a patient with von Hippel-Lindau disease: a case report and review of the literature.

Authors:  Gulcin Ertas; Muzaffer Bedri Altundag; Ali Riza Ucer; Fatih Cankal; Kadri Altundag
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

Review 4.  Isolated haemangioblastoma of spinal cord: report of 18 cases and a review of the literature.

Authors:  P Lunardi; L Cervoni; A Maleci; A Fortuna
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.